OM Quote, Financials, Valuation and Earnings

Integra Lifesciences Holdings has a net margin of -87.01% compared to Outset Medical's net margin of -6.61%. Outset Medical's return on equity of -178.08% beat Integra Lifesciences Holdings's return on equity of -1.88%.

Outset Medical has a consensus price target of $22.25, signalling upside risk potential of 85.26%. On the other hand Integra Lifesciences Holdings has an analysts' consensus of $18.63 which suggests that it could grow by 46.31%. Given that Outset Medical has higher upside potential than Integra Lifesciences Holdings, analysts believe Outset Medical is more attractive than Integra Lifesciences Holdings.

Outset Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Integra Lifesciences Holdings has a beta of 1.268, suggesting its more volatile than the S&P 500 by 26.765%.

Outset Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integra Lifesciences Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outset Medical pays -- of its earnings as a dividend. Integra Lifesciences Holdings pays out -- of its earnings as a dividend.

Outset Medical quarterly revenues are $29.5M, which are smaller than Integra Lifesciences Holdings quarterly revenues of $382.7M. Outset Medical's net income of -$25.6M is lower than Integra Lifesciences Holdings's net income of -$25.3M. Notably, Outset Medical's price-to-earnings ratio is -- while Integra Lifesciences Holdings's PE ratio is 70.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outset Medical is 0.35x versus 0.60x for Integra Lifesciences Holdings. Usually stocks with elevated PS ratios are considered overvalued.

iRhythm Technologies has a net margin of -87.01% compared to Outset Medical's net margin of -19.35%. Outset Medical's return on equity of -178.08% beat iRhythm Technologies's return on equity of -112.03%.

Outset Medical has a consensus price target of $22.25, signalling upside risk potential of 85.26%. On the other hand iRhythm Technologies has an analysts' consensus of $137.33 which suggests that it could grow by 0.84%. Given that Outset Medical has higher upside potential than iRhythm Technologies, analysts believe Outset Medical is more attractive than iRhythm Technologies.

Outset Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison iRhythm Technologies has a beta of 1.343, suggesting its more volatile than the S&P 500 by 34.347%.

Outset Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iRhythm Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outset Medical pays -- of its earnings as a dividend. iRhythm Technologies pays out -- of its earnings as a dividend.

Outset Medical quarterly revenues are $29.5M, which are smaller than iRhythm Technologies quarterly revenues of $158.7M. Outset Medical's net income of -$25.6M is higher than iRhythm Technologies's net income of -$30.7M. Notably, Outset Medical's price-to-earnings ratio is -- while iRhythm Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outset Medical is 0.35x versus 6.90x for iRhythm Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of -87.01% compared to Outset Medical's net margin of 16.85%. Outset Medical's return on equity of -178.08% beat Insulet's return on equity of 43.11%.

Outset Medical has a consensus price target of $22.25, signalling upside risk potential of 85.26%. On the other hand Insulet has an analysts' consensus of $313.60 which suggests that it could grow by 18.65%. Given that Outset Medical has higher upside potential than Insulet, analysts believe Outset Medical is more attractive than Insulet.

Outset Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Insulet has a beta of 1.263, suggesting its more volatile than the S&P 500 by 26.336%.

Outset Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outset Medical pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Outset Medical quarterly revenues are $29.5M, which are smaller than Insulet quarterly revenues of $597.5M. Outset Medical's net income of -$25.6M is lower than Insulet's net income of $100.7M. Notably, Outset Medical's price-to-earnings ratio is -- while Insulet's PE ratio is 45.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outset Medical is 0.35x versus 9.43x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

Stryker has a net margin of -87.01% compared to Outset Medical's net margin of 11.15%. Outset Medical's return on equity of -178.08% beat Stryker's return on equity of 14.2%.

Outset Medical has a consensus price target of $22.25, signalling upside risk potential of 85.26%. On the other hand Stryker has an analysts' consensus of $424.26 which suggests that it could grow by 10.47%. Given that Outset Medical has higher upside potential than Stryker, analysts believe Outset Medical is more attractive than Stryker.

Outset Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Stryker has a beta of 0.929, suggesting its less volatile than the S&P 500 by 7.091%.

Outset Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker offers a yield of 0.85% to investors and pays a quarterly dividend of $0.84 per share. Outset Medical pays -- of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Outset Medical quarterly revenues are $29.5M, which are smaller than Stryker quarterly revenues of $5.9B. Outset Medical's net income of -$25.6M is lower than Stryker's net income of $654M. Notably, Outset Medical's price-to-earnings ratio is -- while Stryker's PE ratio is 51.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outset Medical is 0.35x versus 6.38x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.